Vantage logo

Covid-19 infects global drug stocks

The coronavirus pandemic wiped billions from global drug stock valuations in the first quarter, with the few gainers failing to offset huge losses elsewhere.

Vantage logo

Covid-19 forces Lilly to hit the brakes

As Lilly pauses much of its research owing to the coronavirus pandemic, Vantage takes a look at an estimate of the cash committed to ongoing clinical studies. Clue: it’s…

Vantage logo

On the hunt for a Covid-19 vaccine

As Cepi asks for $2bn to fund development of a vaccine against coronavirus and Moderna moves into the clinic, Vantage takes a look at previous pandemic development costs.

Vantage logo

The cost to Astrazeneca of building Brilinta

Thales, the final Brilinta outcome trial in Astrazeneca’s huge Parthenon programme, has hit – but the UK group’s vast investment in its blood thinner has yet to pay off.